NO323969B1 - Farmasoytisk aktive pyrrolidinderivater - Google Patents

Farmasoytisk aktive pyrrolidinderivater Download PDF

Info

Publication number
NO323969B1
NO323969B1 NO20024598A NO20024598A NO323969B1 NO 323969 B1 NO323969 B1 NO 323969B1 NO 20024598 A NO20024598 A NO 20024598A NO 20024598 A NO20024598 A NO 20024598A NO 323969 B1 NO323969 B1 NO 323969B1
Authority
NO
Norway
Prior art keywords
pyrrolidinecarboxamide
methoxyimino
biphenyl
hydroxy
carbonyl
Prior art date
Application number
NO20024598A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024598L (no
NO20024598D0 (no
Inventor
Anthony Baxter
Serge Halazy
Anna Quattropani
Alexander Scheer
Matthias Schwarz
Russel J Thomas
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20024598D0 publication Critical patent/NO20024598D0/no
Publication of NO20024598L publication Critical patent/NO20024598L/no
Publication of NO323969B1 publication Critical patent/NO323969B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024598A 2000-03-27 2002-09-25 Farmasoytisk aktive pyrrolidinderivater NO323969B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106034 2000-03-27
PCT/EP2001/003171 WO2001072705A1 (en) 2000-03-27 2001-03-20 Pharmaceutically active pyrrolidine derivatives as bax inhibitors

Publications (3)

Publication Number Publication Date
NO20024598D0 NO20024598D0 (no) 2002-09-25
NO20024598L NO20024598L (no) 2002-11-25
NO323969B1 true NO323969B1 (no) 2007-07-23

Family

ID=8168169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024598A NO323969B1 (no) 2000-03-27 2002-09-25 Farmasoytisk aktive pyrrolidinderivater

Country Status (33)

Country Link
US (2) US7211601B2 (de)
EP (1) EP1268419B1 (de)
JP (2) JP2003528854A (de)
KR (1) KR100714585B1 (de)
CN (1) CN1296354C (de)
AR (1) AR029499A1 (de)
AT (1) ATE330940T1 (de)
AU (2) AU5620901A (de)
BG (1) BG107132A (de)
BR (1) BR0109900A (de)
CA (1) CA2401242A1 (de)
CY (1) CY1105519T1 (de)
CZ (1) CZ20023243A3 (de)
DE (1) DE60120940T2 (de)
DK (1) DK1268419T3 (de)
EA (1) EA006424B1 (de)
EE (1) EE200200555A (de)
ES (1) ES2261404T3 (de)
HK (1) HK1054031B (de)
HR (1) HRP20020705A2 (de)
HU (1) HUP0300994A2 (de)
IL (1) IL151912A0 (de)
MX (1) MXPA02009382A (de)
NO (1) NO323969B1 (de)
NZ (1) NZ521060A (de)
PL (1) PL358001A1 (de)
PT (1) PT1268419E (de)
SI (1) SI1268419T1 (de)
SK (1) SK13832002A3 (de)
UA (1) UA74362C2 (de)
WO (1) WO2001072705A1 (de)
YU (1) YU73502A (de)
ZA (1) ZA200206799B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1268418T3 (da) * 2000-03-27 2006-09-25 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer
EP1444225B1 (de) * 2001-06-18 2012-10-10 Merck Serono SA Pyrrolidin oxadiazol- und thiadiazol oxim derivate als oxytozin rezeptor antagonisten
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
EP1567487A4 (de) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
ES2333719T3 (es) * 2003-02-27 2010-02-26 Merck Serono Sa Derivados de pirrolidina en calidad de antagonistas de oxitocina.
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
EA011026B1 (ru) * 2004-02-26 2008-12-30 Лаборатуар Сероно Са Способ получения пирролидиноксимов
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
EP2379524A1 (de) * 2008-12-18 2011-10-26 Boehringer Ingelheim International GmbH Inhibitoren des serotonin-5-ht2b-rezeptors
US9120776B2 (en) 2011-09-22 2015-09-01 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
EP2845850A1 (de) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten
EP2886107A1 (de) 2013-12-17 2015-06-24 ObsEva S.A. Orale Formulierungen von Pyrrolydinderivaten
EP3753921A1 (de) 2014-07-02 2020-12-23 ObsEva S.A. Kristallines (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-on-o-methyloxim und verfahren zur verwendung davon
CN114621962B (zh) * 2022-03-21 2024-05-14 广西大学 花生AhBI-1基因VIGS沉默体系
TW202435864A (zh) 2023-02-09 2024-09-16 大陸商上海葆正醫藥科技有限公司 亞胺化合物及其製備方法和應用
CN117044622A (zh) * 2023-09-22 2023-11-14 贵州师范大学 一种无花瓣芥菜型油菜的选育方式

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33548A (en) 1964-08-05 1972-04-27 Upjohn Co Galactopyranosides which are intermediates for lincomycin
US3555007A (en) 1968-07-22 1971-01-12 Upjohn Co 7-deoxy-7-halo lincomycin d derivatives
US3674647A (en) 1970-10-07 1972-07-04 Upjohn Co Preparation of lincomycin analogues
ZA801424B (en) * 1979-03-12 1981-03-25 Warner Lambert Co Novel antibactrial amide compounds and process means for producing the same
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
GB9316162D0 (en) 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
EP0805681A4 (de) 1995-01-24 1998-05-06 Merck & Co Inc Tokolytische oxytocin-rezeptor-antagonisten
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO2000004005A1 (en) * 1998-07-14 2000-01-27 Ono Pharmaceutical Co., Ltd. Amino acid derivatives and drugs containing the same as the active ingredient
ATE279407T1 (de) * 1998-08-07 2004-10-15 Applied Research Systems Fsh mimetika zur behandlung von infertilität
HUP0201295A3 (en) * 1999-01-27 2002-10-28 Ortho Mcneil Pharm Inc Peptidyl heterocyclic ketones useful as tryptase inhibitors
WO2000048623A1 (en) * 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
EA200100972A1 (ru) * 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
EP1176959B1 (de) * 1999-05-05 2006-03-08 Merck & Co., Inc. Neue prolinverbindungen als mikrobizide mittel
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
DK1268418T3 (da) * 2000-03-27 2006-09-25 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som Bax-inhibitorer

Also Published As

Publication number Publication date
DE60120940T2 (de) 2007-01-25
EE200200555A (et) 2004-06-15
EA200201026A1 (ru) 2003-02-27
KR100714585B1 (ko) 2007-05-07
MXPA02009382A (es) 2003-01-28
EP1268419B1 (de) 2006-06-21
CA2401242A1 (en) 2001-10-04
JP2003528854A (ja) 2003-09-30
DK1268419T3 (da) 2006-10-02
DE60120940D1 (de) 2006-08-03
US7211601B2 (en) 2007-05-01
AR029499A1 (es) 2003-07-02
PT1268419E (pt) 2006-08-31
HK1054031A1 (en) 2003-11-14
CZ20023243A3 (cs) 2003-01-15
IL151912A0 (en) 2003-04-10
JP5580364B2 (ja) 2014-08-27
JP2012149098A (ja) 2012-08-09
HK1054031B (zh) 2007-05-04
ATE330940T1 (de) 2006-07-15
WO2001072705A1 (en) 2001-10-04
KR20020095195A (ko) 2002-12-20
SK13832002A3 (sk) 2003-03-04
BR0109900A (pt) 2003-06-03
YU73502A (sh) 2005-11-28
HRP20020705A2 (en) 2004-12-31
AU5620901A (en) 2001-10-08
NO20024598L (no) 2002-11-25
EP1268419A1 (de) 2003-01-02
US20080167318A1 (en) 2008-07-10
UA74362C2 (uk) 2005-12-15
PL358001A1 (en) 2004-08-09
CN1419541A (zh) 2003-05-21
AU2001256209B2 (en) 2006-02-16
EA006424B1 (ru) 2005-12-29
ZA200206799B (en) 2003-08-26
CY1105519T1 (el) 2010-07-28
HUP0300994A2 (hu) 2003-08-28
SI1268419T1 (sl) 2006-10-31
BG107132A (bg) 2003-04-30
US20030212012A1 (en) 2003-11-13
NZ521060A (en) 2004-05-28
ES2261404T3 (es) 2006-11-16
NO20024598D0 (no) 2002-09-25
CN1296354C (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
JP5580364B2 (ja) 医薬として活性なピロリジン誘導体
JP4602672B2 (ja) プロスタグランジンf受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
AU2001256209A1 (en) Pharmaceutically active pyrrolidine derivatives
JP4426284B2 (ja) ピロリジン・オキサジアゾール−及びチアジアゾール誘導体
JP4511184B2 (ja) オキシトシン・アンタゴニストとしてのトリアゾール類
JP4851085B2 (ja) オキシトシン拮抗物質としてのピロリジン誘導体
JP4350948B2 (ja) オキシトシン調節活性を有するピロリジンエステル誘導体
AU2002319237A1 (en) Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
JP4773335B2 (ja) オキシトシンアンタゴニストとしてのピロリジン誘導体